Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GBM
MCID: GLB002
MIFTS: 67

Glioblastoma (GBM)

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glioblastoma

About this section

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 12 73 20 58 29 54 6 44 70
Glioblastoma Multiforme 12 73 20 58 29 54 6 15 17 70
Gbm 12 58
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 70
Adult Glioblastoma 70

Characteristics:

Orphanet epidemiological data:

58
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3068
MeSH 44 D005909
SNOMED-CT 67 63634009
MESH via Orphanet 45 D005909
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 70 C0017636 C0278878 C1514422 more
Sources

Summaries for Glioblastoma

About this section
GARD : 20 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome. There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to glioma and high grade glioma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are glioblastoma multiforme and abnormal cell morphology

Disease Ontology : 12 A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Wikipedia : 73 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that... more...

Sources

Related Diseases for Glioblastoma

About this section

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 948)
# Related Disease Score Top Affiliating Genes
1 glioma 33.1 TP73-AS1 MIR34A MIR296 MIR222 MIR221 MIR21
2 high grade glioma 32.2 XIST HOTAIRM1 HOTAIR GAS5
3 b-cell lymphoma 31.5 MIR34A MIR21 MIR17HG HOTAIR GAS5
4 brain glioma 31.4 TP73-AS1 MIR34A GAS5
5 nervous system cancer 31.2 MIR34A MIR296 MIR222 MIR21 MIR182
6 central nervous system cancer 31.2 MIR34A MIR296 MIR222 MIR21
7 leukemia, acute lymphoblastic 31.1 XIST MSH2 MIR451A MIR222 MIR221 MIR21
8 medulloblastoma 31.1 MIR34A MIR326 MIR17HG HOTAIR BRCA2
9 melanoma 31.1 XIST MIR34A MIR222 MIR221 MIR182 MIR137
10 leukemia, acute myeloid 31.0 MIR451A MIR34A MIR326 MIR222 MIR221 MIR21
11 bladder cancer 30.9 XIST MIR34A MIR222 MIR221 MIR21 MIR182
12 renal cell carcinoma, nonpapillary 30.9 MIR34A MIR221 MIR21 MIR182 HOTAIR GAS5
13 diffuse large b-cell lymphoma 30.9 MIR222 MIR221 MIR21 MIR17HG HOTAIR
14 colorectal cancer 30.8 XIST NOS2 MSH2 MIR451A MIR34A MIR296
15 prostate cancer 30.7 XIST MSH2 MIR34A MIR296 MIR222 MIR221
16 retinitis pigmentosa 11 30.7 XIST MIR296 HOTAIR
17 lung cancer 30.7 XIST TP73-AS1 NOS2 MIR451A MIR34A MIR296
18 ovarian cancer 30.7 XIST MSH2 MIR34A MIR296 MIR222 MIR221
19 kidney cancer 30.7 MIR21 MIR182 HOTAIR GAS5
20 leukemia, chronic lymphocytic 30.6 MIR34A MIR296 MIR221 MIR21 MIR182 MIR17HG
21 breast cancer 30.6 XIST TP73-AS1 NOS2 MSH2 MIR451A MIR34A
22 myeloma, multiple 30.6 TP73-AS1 MIR21 HOTAIR GAS5
23 nervous system disease 30.5 NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
24 muscular dystrophy, duchenne type 30.5 MIR34A MIR222 MIR221 MIR21
25 pancreatic cancer 30.5 XIST MSH2 MIR34A MIR222 MIR221 MIR21
26 lymphoma, non-hodgkin, familial 30.4 MSH2 MIR34A MIR222 MIR21 MIR182
27 central nervous system disease 30.4 NOS2 MIR34A MIR221 MIR21
28 pancreatic ductal adenocarcinoma 30.3 MIR222 MIR221 MIR21 HOTAIRM1 HOTAIR BRCA2
29 primary biliary cholangitis 30.3 MIR451A MIR326 MIR296 MIR21
30 thyroid cancer, nonmedullary, 1 30.3 MIR222 MIR221 HOTAIR
31 hepatocellular carcinoma 30.2 XIST TP73-AS1 NOS2 MSH2 MIR34A MIR222
32 esophageal cancer 30.1 XIST MIR34A MIR21 HOTAIR GAS5 BRCA2
33 glioma susceptibility 1 11.6
34 goodpasture syndrome 11.6
35 giant cell glioblastoma 11.5
36 brain glioblastoma multiforme 11.4
37 glial tumor 11.4
38 gliosarcoma 11.3
39 glioma susceptibility 3 11.3
40 glioblastoma proneural subtype 11.3
41 glioblastoma mesenchymal subtype 11.3
42 glioblastoma neural subtype 11.3
43 idh-wildtype glioblastoma 11.2
44 idh-mutant glioblastoma 11.2
45 adult spinal cord glioblastoma multiforme 11.2
46 glioblastoma classical subtype 11.2
47 anti-basement membrane glomerulonephritis 11.1
48 gliomatosis cerebri 11.1
49 rapidly progressive glomerulonephritis 11.1
50 focal segmental glomerulosclerosis 10 11.0

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma
Sources

Symptoms & Phenotypes for Glioblastoma

About this section

Human phenotypes related to Glioblastoma:

31 58 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glioblastoma multiforme 31 obligate (100%) HP:0012174
2 abnormal cell morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0025461
3 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
6 visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000572
7 abnormal corpus callosum morphology 58 31 frequent (33%) Frequent (79-30%) HP:0001273
8 language impairment 58 31 frequent (33%) Frequent (79-30%) HP:0002463
9 paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0003470
10 cerebral edema 58 31 frequent (33%) Frequent (79-30%) HP:0002181
11 mood changes 58 31 frequent (33%) Frequent (79-30%) HP:0001575
12 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
13 seizure 31 occasional (7.5%) HP:0001250
14 seizures 58 Occasional (29-5%)
15 abnormality of the cerebral white matter 58 Frequent (79-30%)
16 abnormality of nervous system physiology 58 Frequent (79-30%)
17 glioblastoma 58 Obligate (100%)

UMLS symptoms related to Glioblastoma:


seizures; headache
Sources

Drugs & Therapeutics for Glioblastoma

About this section

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 577)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Trioxsalen Approved Phase 3 3902-71-4 5585
6
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
7
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
8
Ethanol Approved Phase 2, Phase 3 64-17-5 702
9
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
10
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
11
Donepezil Approved Phase 3 120014-06-4 3152
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
14
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
16
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
17
Fluorometholone Approved, Investigational Phase 3 426-13-1 9878
18
Naphazoline Approved, Investigational Phase 3 835-31-4 4436
19
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
20
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
21
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
22
Etoposide Approved Phase 3 33419-42-0 36462
23
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
24
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
25
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
26
Iodine Approved, Investigational Phase 3 7553-56-2 807
27
nivolumab Approved Phase 3 946414-94-4
28
Povidone Approved Phase 3 9003-39-8 131751496
29
Povidone-iodine Approved Phase 3 25655-41-8
30
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
31
Carmustine Approved, Investigational Phase 3 154-93-8 2578
32
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
33
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
34
Norepinephrine Approved Phase 3 51-41-2 439260
35
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
37
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2
38
Cediranib Investigational Phase 3 288383-20-0 9933475
39 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
40
Rindopepimut Investigational Phase 3 1108208-65-6
41
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
42
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
43
Semustine Experimental, Investigational Phase 3 13909-09-6
44
Cadexomer iodine Experimental Phase 3 94820-09-4
45
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
46
Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Dihematoporphyrin Ether Phase 3
48 Interferon-alpha Phase 3
49 Serotonin Uptake Inhibitors Phase 2, Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 1520)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
3 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
4 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
5 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
7 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
8 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
9 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
10 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
11 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
12 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
14 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
15 Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma Completed NCT01290939 Phase 3 lomustine
16 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
17 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
18 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
19 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
20 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
21 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
22 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
23 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
24 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
25 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
26 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
27 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
28 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
29 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
30 Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) Completed NCT03419403 Phase 3 Steroid eye drop;Ophthalmic steroid ointment;Temozolomide;depatuxizumab mafodotin;Vasoconstrictor eye drop
31 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
32 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
33 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
34 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
35 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Completed NCT01805453 Phase 3 Losartan;Placebo
36 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
37 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
38 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
39 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
40 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
41 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
42 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
43 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
44 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
45 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
46 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
47 Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Completed NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
48 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTINâ„¢, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
49 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
50 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carmustine

Cochrane evidence based reviews: glioblastoma

Sources

Genetic Tests for Glioblastoma

About this section

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 29
2 Glioblastoma Multiforme 29
Sources

Anatomical Context for Glioblastoma

About this section

MalaCards organs/tissues related to Glioblastoma:

40
Brain, T Cells, Endothelial, Spinal Cord, Myeloid, Bone, Breast
Sources

Publications for Glioblastoma

About this section

Articles related to Glioblastoma:

(show top 50) (show all 32928)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 61 54 47
19773441 2009
2
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 61 54 47
18577219 2008
3
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. 54 61 47
17721077 2007
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
5
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. 47 61
20227367 2010
6
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 61 47
19559015 2009
7
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. 47 61
19159078 2009
8
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 61 47
18759060 2009
9
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. 61 47
19013014 2008
10
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. 61 47
18765229 2008
11
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. 61 47
18829576 2008
12
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
13
Extensive modulation of a set of microRNAs in primary glioblastoma. 61 47
16039986 2005
14
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. 47 61
16024602 2005
15
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
16
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
17
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 61 54
19937796 2010
18
miR-182 as a prognostic marker for glioma progression and patient survival. 47
20472885 2010
19
Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. 54 61
20514402 2010
20
Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. 54 61
20177775 2010
21
Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. 61 54
20303140 2010
22
New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. 54 61
20305620 2010
23
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. 54 61
20428822 2010
24
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 54 61
20428809 2010
25
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 54 61
20195615 2010
26
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. 54 61
20388502 2010
27
Amplicons on chromosome 12q13-21 in glioblastoma recurrences. 61 54
19839052 2010
28
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 61 54
20467331 2010
29
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. 54 61
20199106 2010
30
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. 61 54
20372840 2010
31
The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. 54 61
19937366 2010
32
Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. 61 54
20302512 2010
33
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. 54 61
20457618 2010
34
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. 61 54
20309962 2010
35
Integrin alpha 6 regulates glioblastoma stem cells. 61 54
20452317 2010
36
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. 54 61
20457619 2010
37
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. 54 61
19841865 2010
38
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. 61 54
20096265 2010
39
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 61 54
19856144 2010
40
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. 61 54
20307616 2010
41
Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. 61 54
20162618 2010
42
FasL gene knock-down therapy enhances the antiglioma immune response. 54 61
20406899 2010
43
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 61 54
19810093 2010
44
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 54 61
20308316 2010
45
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. 61 54
20436671 2010
46
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. 61 54
20360941 2010
47
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. 61 54
20371721 2010
48
Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. 54 61
20298756 2010
49
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. 61 54
20127344 2010
50
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 54 61
20412570 2010
Sources

Variations for Glioblastoma

About this section

ClinVar genetic disease variations for Glioblastoma:

6 (show top 50) (show all 288)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCOR NM_001123385.2(BCOR):c.3881_3882AG[1] (p.Leu1296fs) Microsatellite other 284290 rs886042842 GRCh37: X:39922288-39922289
GRCh38: X:40063035-40063036
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV other 438772 rs1556339256 GRCh37: X:70357729-70357729
GRCh38: X:71137879-71137879
3 H3-3A NM_002107.6(H3-3A):c.103G>A (p.Gly35Arg) SNV other 438766 rs1553260624 GRCh37: 1:226252155-226252155
GRCh38: 1:226064454-226064454
4 BRCA2 NM_000059.3(BRCA2):c.1399A>T (p.Lys467Ter) SNV Pathogenic 51118 rs80358427 GRCh37: 13:32907014-32907014
GRCh38: 13:32332877-32332877
5 BRCA2 NM_000059.3(BRCA2):c.5791C>T (p.Gln1931Ter) SNV Pathogenic 51939 rs80358807 GRCh37: 13:32914283-32914283
GRCh38: 13:32340146-32340146
6 MSH2 NM_000251.2(MSH2):c.1958_1965del (p.Asn653fs) Deletion Pathogenic 590849 rs1558518449 GRCh37: 2:47702360-47702367
GRCh38: 2:47475221-47475228
7 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
8 BRCA2 NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter) SNV Pathogenic 51952 rs80358814 GRCh37: 13:32914349-32914349
GRCh38: 13:32340212-32340212
9 BRCA2 NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter) SNV Pathogenic 51129 rs80358435 GRCh37: 13:32893291-32893291
GRCh38: 13:32319154-32319154
10 BRCA2 NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter) SNV Pathogenic 52808 rs397508045 GRCh37: 13:32893238-32893238
GRCh38: 13:32319101-32319101
11 BRCA2 NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter) SNV Pathogenic 51041 rs80358391 GRCh37: 13:32893246-32893246
GRCh38: 13:32319109-32319109
12 BRCA2 NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter) SNV Pathogenic 37819 rs80358557 GRCh37: 13:32911601-32911601
GRCh38: 13:32337464-32337464
13 BRCA2 NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter) SNV Pathogenic 37936 rs80358721 GRCh37: 13:32913457-32913457
GRCh38: 13:32339320-32339320
14 BRCA2 NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter) SNV Pathogenic 38076 rs80358920 GRCh37: 13:32920978-32920978
GRCh38: 13:32346841-32346841
15 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
16 BRCA2 NM_000059.3(BRCA2):c.4243G>T (p.Glu1415Ter) SNV Pathogenic 37890 rs397507327 GRCh37: 13:32912735-32912735
GRCh38: 13:32338598-32338598
17 BRCA2 NM_000059.4(BRCA2):c.6656C>G (p.Ser2219Ter) SNV Pathogenic 52149 rs80358893 GRCh37: 13:32915148-32915148
GRCh38: 13:32341011-32341011
18 BRCA2 NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe) SNV Pathogenic 52430 rs80359014 GRCh37: 13:32936733-32936733
GRCh38: 13:32362596-32362596
19 BRCA2 NM_000059.4(BRCA2):c.7988A>T (p.Glu2663Val) SNV Pathogenic 52462 rs80359031 GRCh37: 13:32937327-32937327
GRCh38: 13:32363190-32363190
20 BRCA2 NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His) SNV Pathogenic 52515 rs41293511 GRCh37: 13:32937506-32937506
GRCh38: 13:32363369-32363369
21 BRCA2 NM_000059.4(BRCA2):c.8488-1G>A SNV Pathogenic 38164 rs397507404 GRCh37: 13:32945092-32945092
GRCh38: 13:32370955-32370955
22 BRCA2 NM_000059.4(BRCA2):c.9294C>G (p.Tyr3098Ter) SNV Pathogenic 38229 rs80359200 GRCh37: 13:32968863-32968863
GRCh38: 13:32394726-32394726
23 BRCA2 NM_000059.4(BRCA2):c.9382C>T (p.Arg3128Ter) SNV Pathogenic 52826 rs80359212 GRCh37: 13:32968951-32968951
GRCh38: 13:32394814-32394814
24 BRCA2 NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter) SNV Pathogenic 37989 rs41293497 GRCh37: 13:32914174-32914174
GRCh38: 13:32340037-32340037
25 BRCA2 NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter) SNV Pathogenic 38099 rs80358972 GRCh37: 13:32930609-32930609
GRCh38: 13:32356472-32356472
26 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
27 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
28 TP53 NM_001126115.1(TP53):c.-3A>C SNV Likely pathogenic 376628 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
29 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
30 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
31 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
32 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
33 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys) SNV Likely pathogenic 376470 rs1057519925 GRCh37: 3:178928079-178928079
GRCh38: 3:179210291-179210291
34 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
35 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Likely pathogenic 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
36 EGFR NM_005228.5(EGFR):c.2156G>C (p.Gly719Ala) SNV Likely pathogenic 45225 rs121913428 GRCh37: 7:55241708-55241708
GRCh38: 7:55174015-55174015
37 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
38 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
39 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
40 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val) SNV Likely pathogenic 40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
41 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
42 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg) SNV Likely pathogenic 45466 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
43 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
44 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
45 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
46 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
47 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
48 ATM , C11orf65 NM_000051.3(ATM):c.8535G>A (p.Trp2845Ter) SNV Likely pathogenic 555284 rs1555138291 GRCh37: 11:108216586-108216586
GRCh38: 11:108345859-108345859
49 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
50 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297

Copy number variations for Glioblastoma from CNVD:

7 (show top 50) (show all 797)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13758 1 1 28000000 Copy number Glioblastoma
10 13761 1 1 28000000 Deletion Glioblastoma multiforme
11 13763 1 1 28000000 Gain Glioblastoma multiforme
12 13775 1 1 39600000 Loss Glioblastoma multiforme
13 13792 1 1 51300000 Loss Glioblastoma multiforme
14 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
15 14314 1 107000000 111600000 Gain Glioblastoma multiforme
16 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
17 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
18 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
19 16435 1 124300000 247249719 Gain Glioblastoma multiforme
20 16436 1 124300000 247249719 Gain Glioblastoma multiforme
21 16437 1 124300000 247249719 Gain Glioblastoma multiforme
22 16444 1 124300000 247249719 Loss Glioblastoma multiforme
23 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
24 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
25 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
26 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
27 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
28 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
29 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
30 23682 1 172900000 185800000 Gain Glioblastoma multiforme
31 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
32 25428 1 189000000 197500000 Gain Glioblastoma multiforme
33 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
34 26137 1 197500000 205300000 Amplification LRRN2 Glioblastoma multiforme
35 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
37 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
38 26146 1 197500000 205300000 Amplificationlication MDM2 Glioblastoma multiforme
39 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
40 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
41 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
42 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
43 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
44 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
45 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
46 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
47 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
48 31747 1 30500000 171200000 Gain Glioblastoma multiforme
49 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
50 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
Sources

Expression for Glioblastoma

About this section
Search GEO for disease gene expression data for Glioblastoma.
Sources

Pathways for Glioblastoma

About this section

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.66 MIR451A MIR34A MIR326 MIR222 MIR221 MIR21
Sources

GO Terms for Glioblastoma

About this section

Cellular components related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.02 MIR451A MIR34A MIR222 MIR221 MIR21

Biological processes related to Glioblastoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.9 NOS2 MIR451A MIR34A MIR21
2 negative regulation of cell migration GO:0030336 9.81 MIR451A MIR34A MIR21 MIR137
3 negative regulation of angiogenesis GO:0016525 9.78 MIR34A MIR222 MIR21 MIR137
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.73 MIR451A MIR21 MIR137
5 negative regulation of protein kinase B signaling GO:0051898 9.72 MIR451A MIR34A MIR137
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 MIR222 MIR221 MIR21
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 MIR222 MIR221 MIR21
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.67 MIR34A MIR182 MIR137
9 miRNA mediated inhibition of translation GO:0035278 9.67 MIR222 MIR221 MIR21 MIR182
10 response to X-ray GO:0010165 9.61 MSH2 BRCA2
11 negative regulation of cell adhesion molecule production GO:0060354 9.59 MIR222 MIR221
12 positive regulation of axon regeneration GO:0048680 9.58 MIR222 MIR221
13 negative regulation by host of viral genome replication GO:0044828 9.58 MIR222 MIR221
14 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR451A MIR221 MIR21
15 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.57 MIR222 MIR221
16 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.46 MIR222 MIR221
17 positive regulation of Schwann cell migration GO:1900149 9.43 MIR222 MIR221
18 negative regulation of interleukin-21 production GO:0032705 9.33 MIR222 MIR221 MIR21
19 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221
20 gene silencing by miRNA GO:0035195 9.32 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
21 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR222 MIR221
22 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.26 MIR34A MIR21 MIR182 MIR137

Molecular functions related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
Sources

Sources for Glioblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....